Tackling reproducibility in academic preclinical drug discovery

Stephen V Frye¹, Michelle R Arkin², Cheryl H Arrowsmith³, P Jeffrey Conn⁴, Marcie A Glicksman⁵, Emily A Hull-Ryde¹, Barbara S Slusher⁶

Affiliations

¹ Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7363, USA.
² Small Molecule Discovery Center, School of Pharmacy, University of California at San Francisco, 1700 4th Street, Box 2552, San Francisco, California 94143, USA.
³ Structural Genomics Consortium, University of Toronto, Suite 700, MaRS South Tower, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
⁴ Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, 1205 LH, Nashville, Tennessee 37232-0697, USA.
⁵ ORIG3N, 27 Drydock Avenue, Boston, Massachusetts 02210, USA.
⁶ Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Rangos Suite 277, 855 North Wolfe Street, Baltimore, Maryland 21205, USA.

PMID: 26388229
DOI: 10.1038/nrd4737

Review

Tackling reproducibility in academic preclinical drug discovery

Stephen V Frye et al. Nat Rev Drug Discov. 2015 Nov.

. 2015 Nov;14(11):733-4.

doi: 10.1038/nrd4737. Epub 2015 Sep 21.

Authors

Stephen V Frye¹, Michelle R Arkin², Cheryl H Arrowsmith³, P Jeffrey Conn⁴, Marcie A Glicksman⁵, Emily A Hull-Ryde¹, Barbara S Slusher⁶

Affiliations

¹ Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7363, USA.
² Small Molecule Discovery Center, School of Pharmacy, University of California at San Francisco, 1700 4th Street, Box 2552, San Francisco, California 94143, USA.
³ Structural Genomics Consortium, University of Toronto, Suite 700, MaRS South Tower, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
⁴ Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, 1205 LH, Nashville, Tennessee 37232-0697, USA.
⁵ ORIG3N, 27 Drydock Avenue, Boston, Massachusetts 02210, USA.
⁶ Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Rangos Suite 277, 855 North Wolfe Street, Baltimore, Maryland 21205, USA.

PMID: 26388229
DOI: 10.1038/nrd4737

Abstract

The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.

PubMed Disclaimer

References

1. Nat Rev Drug Discov. 2014 Dec;13(12):875-6 - PubMed
1. Nature. 2014 Sep 25;513(7519):481-3 - PubMed
1. Elife. 2014 Dec 10;3:null - PubMed
1. Nat Chem Biol. 2015 Aug;11(8):536-41 - PubMed
1. Nat Rev Drug Discov. 2011 Aug 31;10(9):712 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tackling reproducibility in academic preclinical drug discovery

Affiliations

Tackling reproducibility in academic preclinical drug discovery

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources